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SIMVASTATIN RESTORES DOWN-REGULATED GATA-6 EXPRESSION
IN PULMONARY HYPERTENSIVE RATS
Bin Liu, Xiao-qin Wang, Li Yu, Tong-fu Zhou, Xian-min Wang,
and Han-min Liu  Department of Pediatric Cardiology, West China Second
University Hospital, University, Chengdu, Sichuan, China
 Vascular smooth muscle cell proliferation has been known to be predominant in vascular re-
modeling of pulmonary hypertensive. The GATA family proteins, a group of zinc ﬁnger transcription
factors, play an important role during cell proliferation. The aim of present study was to investi-
gate the expression of GATA-6 gene in experimental pulmonary hypertensive rats and explore the
effect of regulation of GATA-6 expression by simvastatin on pulmonary vascular remodeling. The
male Sprague-Dawley rats model was established with receiving pneumonectomy and monocrotaline
(MCT) administration. Right pulmonary artery remodeling in these animals was compared with
untreated rats or rats receiving simvastatin. The level of GATA-6 mRNA and protein expression
was detected by reverse transcriptase–polymerase chain reaction (RT-PCR) and Western blotting,
respectively. Pneumonectomized, MCT-treated rats had signiﬁcantly increased mean pulmonary ar-
terial pressure (mPAP), RV/(LV + S) ratio (ratio of the right ventricular to left ventricular and
septum weights), vascular occlusion scores (VOSs), and percent media wall thickness on day 35,
all the indices were signiﬁcantly decreased after simvastatin administration in these rats. The level
of GATA-6 mRNA and protein were markedly decreased in these pneumonectomy and MCT-treated
rats, and they were signiﬁcantly up-regulated in these rats after receiving simvastatin. These results
indicate that the development and progression of pulmonary hypertension is prevented by simvas-
tatin by up-regulating GATA-6 expression in the lung tissue.
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Hypertensive pulmonary vascular disease is characterized by pulmonary vas-
cular remodeling, involving abnormal proliferation of vascular endothelial
and smooth muscle cells and extracellular matrix deposition, leading to oc-
clusion of pulmonary arterioles, pulmonary hypertension, right ventricular
failure, and death. Pulmonary arterial endothelial cell injury are consid-
ered prerequisites for the induction of advanced vascular remodeling in
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pulmonary arterial hypertension [1–4]. Migration, proliferation, and ma-
trix synthesis of pulmonary artery smooth muscle cells play a key role in
pulmonary vascular remodeling. Normal adult pulmonary arterial smooth
muscle cells do not migrate, grow, or synthesize matrix once normal devel-
opment is completed. Dysfunction of endothelium and elevated shear stress
may result in smooth muscle cells proliferation, migration, and matrix syn-
thesis. Increase in shear stress due to high ﬂow modulates production of
platelet-derived growth factor, transforming growth factor-β, nitric oxide,
and transcription factors of the GATA family that regulate cell growth, mi-
gration, and matrix synthesis [5, 6].
The GATA family proteins are a group of zinc ﬁnger transcription fac-
tors that play an important role during mammalian organ morphogenesis,
cell proliferation, and sex differentiation [7]. These factors bind to a con-
sensus DNA motif (A/T)GATA(A/G) in the promoters of target genes in a
variety of tissues [7]. Six GATA family members have been identiﬁed in ver-
tebrates and can be divided into 2 groups based on their tissue distribution
and homology: GATA-1, -2, and -3 and GATA-4, -5, and -6 [8]. GATA-1, -2,
and -3 genes are predominantly expressed in hematopoietic cells where they
are involved in proliferation and differentiation of several cell lineages [9–
12]. GATA-4, -5, and -6 are expressed in heart, liver, lungs, and the gastroin-
testinal tract where they mediate tissue-speciﬁc gene expression, and GATA-
6 is the only member of the GATA family expressed in vascular smooth mus-
cle cells (VSMCs) [13–17].
Analysis of vascular smooth muscle cells has demonstrated an important
role of GATA-6 in regulating cell proliferation in response to mitogenic or
mechanical stimulation. GATA-6 mRNA levels are down-regulated in pro-
liferating vascular smooth muscle cells, suggesting that GATA-6 expression
is linked to the cell cycle in these cells and plays as an important regula-
tor of the VSMC phenotype [18–20]. More speciﬁcally, forced expression
of GATA-6 in vascular smooth muscle cells induces growth arrest through a
mechanism involving enhanced expression of the cyclin-dependent kinase
inhibitor p21 [20, 21]. In vivo, adenovirus- mediated gene transfer of GATA-
6 in balloon-injured carotid arteries prevented vessel lesions associated with
vascular smooth muscle cell phenotypic modulation [21]. Interestingly, lam-
inar shear stress was recently demonstrated to activate transcription factor
GATA-6 [22], which binds to a GATA consensus element located in the re-
gion of downstream gene promoter regulating these gene expression. A
study in vitro reveals that GATA-6 regulates a set of genes associated with syn-
thetic SMC functions and suggests that this transcriptional pathway may be
independent from myocardin-induced SMC differentiation in VSMCs. An
unbiased microarray screen of genes regulated by GATA-6 in VSMCs identi-
ﬁes that endothelin-1 and angiotensin 1a (AT1a) receptor genes are direct
GATA-6 target genes [23]. Based on these studies, we speculate that activitySimvastatin and GATA-6 Expression in PH Rats 413
of transcription factor GATA-6 may be regulated by disturbed laminar shear
stresses occurring in pulmonary hypertension.
The 3-hydroxymethyl-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase inhibitors, statins, improve cardiovascular outcomes independent of
their effects on cholesterol reduction [24]. The immunosuppressive and
anti-inﬂammatory properties of statins [25] may contribute to the improved
survival of patients with atherosclerosis [24, 26]. Statins can suppress en-
dothelial and vascular smooth muscle cell proliferative and inﬂammatory
responses to injury [27, 28]. These effects involve inhibition of isopreny-
lation of Rho and Rac family GTPases that couple growth factor receptors
to the intracellular mitogen-activated protein/extracellular signal-regulated
kinase (MAP/ERK) kinase signaling pathways and induction of the cell cy-
cle inhibitor p27Kip1 [27, 28]. Statins also improve endothelium-dependent
relaxation through mechanisms that involve induction of endothelial nitric
oxide synthase (eNOS) and nitric oxide production [29, 30]. Several stud-
ies demonstrate that simvastatin, a member of the statin family, attenuates
pulmonary vascular remodeling in rat neointimal and hypoxic models of
pulmonary arterial hypertension (PAH) [31–33]. Interestingly, simvastatin is
recently demonstrated in vitro to induce the expression of smooth muscle α-
actin (SM-a-actin) and major histocompatibility complex (SM-MHC), highly
speciﬁc markers of differentiated phenotype [34]. So we speculated whether
pleiotropic atheroprotective effects of HMG-CoA reductase inhibitors may
be mediated by the expression of other members of GATA family that play
an important role in cell proliferation.
In this study, we used an animal model of pulmonary hypertension
by combination of monocrotaline (MCT) administration with pneumonec-
tomy to investigate the efﬁcacy of simvastatin and its mechanism of revers-
ing established neointimal vascular occlusion and pulmonary hypertension.
We showed that the expression of GATA-6 mRNA and protein was down-
regulated in this pulmonary hypertension model, which was reversed by sim-
vastatin administration.
MATERIALS AND METHODS
Animal Model
Pathogen-free male Sprague-Dawley rats weighing between 300 and
400 g (12 weeks old) were used for this study. All animals were obtained
from Sichuan University Animal Centre (Sichuan, Chendu, China) and re-
ceived humane care. On day 0, rats were anesthetized by an intraperitoneal
injection of 10% chloral hydrate (400 mg/kg) and injected subcutaneously
atropine sulfate (50 µg/kg) in the right hindlimb. Left pneumonectomy
was performed as previously described [35]. On day 7, rats were injected414 B. Liu et al.
subcutaneously in the nape with monocrotaline (MCT) (60 mg/kg; Sigma,
USA). MCT was dissolved in 0.5 N HCl and adjusted to pH 7.4 with 0.5 N
NaOH solution. Rats were housed with a 12/12-hour light/dark cycle and
given water and standard rat chow ad libitum.
Treatment Groups
Pneumonectomized rats were randomized to receive simvastatin or ve-
hicle by daily gavage, or neither simvastatin nor vehicle. Six groups were
studied: Rats in group PMV1−35 (n = 12) received a vehicle from days 1 to
35. Group PMV21−35(n = 12) received a vehicle from days 21 to 35. Group
PMS1−35 (n = 12) received simvastatin (2 mg/kg per day) [31] from days
1 to 35. Group PMS21−35(n = 12) received simvastatin (2 mg/kg per day)
from days 21 to 35. Groups PM1−21 (n = 10) and PM1−35 (n = 12) received
neither simvastatin nor vehicle, and were sacriﬁced on day 21 or 35 (post
pneumonectomy) to provide reference point for disease progression in this
model. Ten additional rats were studied as a control group without any inter-
vention. On day 35 after pneumonectomy, rats were sacriﬁced and organs
harvested for the following analysis.
Hemodynamic Studies and Tissue Preparation
On day 35, rats were anesthetized with an intraperitoneal injection of
10% chloral hydrate. Mean pulmonary arterial pressures (mPAPs) were
measured as previously described [36, 37]. After exsanguination, the right
lung, right ventricle, left ventricle, and septum were collected for histology
[36, 37]. Tissues were ﬁxed in 10% neutral-buffered formalin, parafﬁn em-
bedded, and sectioned. After EVG (elastin-van Gieson) staining, lung sec-
tions were examined histologically for evidence of pulmonary vascular dis-
ease. The severity of pulmonary vascular neointimal formation was assessed
in 50 panacinar arteries from each animal. The severity of neointimal forma-
tion was expressed as the vascular occlusion score (VOS), which was scored
according to the criteria of Okada and coworkers [35]. Brieﬂy, the absence
of neointimal formation or luminal occlusion equals grade 0; the presence
of neointimal formation causing less than 50% luminal occlusion equals
grade 1; the presence of neointimal formation causing greater than 50%
luminal occlusion equals grade 2. An average score for 50 vessels (bounded
by 0 and 2) was calculated for each animal. Samples of right lung were im-
mediately placed in liquid nitrogen for extraction of total RNA.
Pulmonary Artery Morphometry
Analysis of each section was carried out in a blinded fashion. To assess
the degree of medial thickening of muscular pulmonary arteries, images of
30 to 50 vessels were recorded in subsets of animals at × 400. Each arterySimvastatin and GATA-6 Expression in PH Rats 415
was classiﬁed by the structure of the accompanying airway as terminal bron-
chiole, respiratory bronchiole, alveolar duct, or alveolar wall. The software
Image-Pro plus, version 4.5.0.29, was used to measure mean arterial diam-
eter (between external elastic laminae) and media thickness (between in-
ternal and external elastic laminae) in complete muscular arteries that ac-
companied terminal and respiratory bronchioles. The percent medial wall
thickness (%WT) was expressed as %WT = (media thickness × 2)/external
diameter × 100 [38].
GATA-6 Gene Expression Analysis
RNA Isolate and RT-PCR
Total RNA from rat lung was isolated using Trnzol (Tiantgen, China).
Reverse transcriptase–polymerase chain reaction (RT-PCR) was used to am-
plify portions of the rat GATA-6 gene (GATA-6; GenBank accession number
NM019185) and β-actin (β-actin; GenBank accession number NM031144)
from rat lung. The primers used were
GATA-6, forward: 5 -CCCAGCGCAGACCTGTTGGAGGACC
GATA-6, reverse: 5 -TGTGACAGTTGGCACAGGACAG
β−Actin, forward: 5 -GACCCAGATCATGTTTGAGACC
β−Actin, reverse: 5 -GCAGTAATCTCCTCCTGCATCC
Reverse transcription was carried out with 1 µgo ft o t a lR N Ai nar e a c t i o n
volume of 20 µL using ReverTra Ace-a kit (ToYoBo) following the provided
instructions. Following the reverse transcription of RNA template, 1 µLo f
the synthesized cDNA was ampliﬁed by PCR. The cycling parameters for
each primer pair were analyzed independently in preliminary experiments.
The PCR for GATA-6 was conducted at 95◦C for 2 minutes, 95◦Cf o r3 0
seconds, 61◦C for 45 seconds, 72◦C for 45 seconds for 33 cycles, followed by
an additional 72◦C 10 minutes for elongation in the ﬁnal cycle. The PCR
for β-actin was conducted at 94◦C for 3 minutes, 94◦C for 30 seconds, 61◦C
for 30 seconds, 72◦C for 1 minutes for 30 cycles, followed by an additional
72◦C 5 minutes for elongation in the ﬁnal cycle. Finally, the RT-PCR product
was analyzed by gel electrophoresis in a 1% agarose gel, stained by ethidium
bromide (Sigma, USA) and then visualized under UV (ultraviolet) light. Gel
electrophoretic analysis was performed with a UVP GelWorks system (1D
Intermediate Version 3.01; USA) to quantify the relative levels of GATA-6 to
β-actin.
Western Blot Analysis
Whole-cell lysates were prepared and Western blot analyses were per-
formed to detect GATA-6 protein expression. In brief, 100 mg of lung tis-
sue was homogenated with 1 ml of tissue protein lysis buffer (MT-CelLytics;416 B. Liu et al.
Biocolors, China). Equivalent amounts of protein (100 µg) were separated
by 10% sodium dedecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) minigels for approximately 100 minutes at 200 V to separate the re-
gion between 50 and 60 kDa and were electroblotted onto polyvinylidene di-
ﬂuoride transfer membrane (Roche, Germany). Blocked membranes were
incubated with polyclonal antibody GATA-6 (Santa Cruz; 1:750) in Tris-
buffered saline supplemented with 0.05% of Tween-20 (TTBS) plus 1%
nonfat milk overnight at 4◦C. The GATA-6 antibody recognizes the ﬁrst
20 amino acids at the C-terminus of recombinant human GATA-6. No
blocking peptides are available for these antibodies. Following extensive
washing with TTBS, membranes were incubated with a 1:1000 dilution
of horseradish peroxidase–conjugated goat anti-rabbit immunoglobulin G
(IgG) secondary antibodies (Santa Cruz; 1:1000) in TTBS plus 5% milk for
1 hour at room temperature. After extensive washing with TTBS, protein-
antibody complexes were visualized by the enhanced chemiluminescene de-
tection system (Pierce, USA). Membranes were reprobed for actin (Santa
Cruz; 1:2000).
Statistical Analysis
Data were expressed as means ± SD. One-way analysis of variance
(ANOVA) was used to compare means between groups and the Newman-
Keuls method for post hoc multiple comparisons assuming unequal vari-
ances using SPSS13.0 software. A P value of <.05 was taken to indicate that
conventional statistical signiﬁcance had been achieved.
RESULTS
Simvastatin Prevented Development of Pulmonary Arterial
Hypertension
Rats in group PM1−21 gradually developed severe pulmonary arterial hy-
pertension (PAH) by day 21 (Figure 1A). Four out of 12 rats in group PM1−35
died by day 35 and the remainder demonstrated progression to severe PAH
(Figure 1A).
All simvastatin-treated rats in group PMS1−35 survived the entire course
of the study (35 days). Two of 12 rats in group PMS21−35 died by day
35. Simvastatin delayed or partly reversed PAH and decreased mPAP in
group PMS1−35 or PMS21−35, compared with the vehicle-treated rats in group
PMV1−35 or PMV21−35 on day 35, respectively (Figure 1B).
Right Ventricular Hypertrophy
By day 35, pulmonary hypertensive rats demonstrated signiﬁcant right
ventricular hypertrophy. The ratio of the right ventricular to left ventricularSimvastatin and GATA-6 Expression in PH Rats 417
FIGURE 1 Simvastatin prevents the development and progression of pulmonary arterial hypertension
in pneumonectomized, MCT-treated rats. (A) Mean pulmonary arterial pressures (mPAPs) in group
PM1−21 (pneumonectomized, MCT-treated rats that were sacriﬁced on day 21; n = 10), Group PM1−35
(pneumonectomized, MCT-treated rats that were sacriﬁced on day 35; n = 8), and control (normal
rats; n = 10). Bars are means ± SD. *P < .001 for groups PM1−21 and PM1−35 versus control; #P <
.001 for group PM1−21 versus group PM1−35.( B) Mean pulmonary arterial pressures (mPAPs) in group
PM1−35 as stated in A, group PMV1−35 (MCT-treated, pneumonectomized rats that received vehicle from
days 1 to 35; n = 9), group PMS1−35 (MCT-treated, pneumonectomized rats that received simvastatin [2
mg/kg per day] from days 1 to 35; n = 12), group PMV21−35 (MCT-treated, pneumonectomized rats that
received vehicle from days 21 to 35; n = 8), group PMS21−35 (MCT-treated, pneumonectomized rats that
received simvastatin [2 mg/kg per day] from days 21 to 35; n = 10). Bars are means ± SD.
§P < .001 for
group PMS1−35 versus group PMV1−35; ∗∗P < .001 for group PMS21−35 versus group PMV21−35; ∗∗∗P <
.001 for Group PMS1−35 versus group PMS21−35.
and septum weights, RV/(LV + S), of pulmonary hypertensive rats signiﬁ-
cantly increased in comparison with normal rats (Figure 2A).
Simvastatin prevented progression and partly reversed established right
ventricular hypertrophy of diseased rats on day 35, with groups PMS1−35
and PMS21−35 showing lower RV/(LV + S) ratio (Figure 2B) compared with
groups PMV1−35 and PMV21−35, respectively (Figure 2B).
FIGURE 2 Simvastatin prevents the development and progression of right ventricular hypertrophy in
pneumonectomized, MCT-treated rats. (A) Ratios of right vertricular weight to left ventricular and inter-
ventricular septal weights [RV/(LV + S)] are shown among the 3 groups of rats as stated in Figure 1A.
Bars are means ± SD. ∗P < .001 for groups PM1−21 and PM1−35 versus control; #P < .001 for group
PM1−35 versus group PM1−21.( B) Ratios of RV/(LV + S) are shown for the 5 groups of rats as stated in
Figure 1B. Bars are means ± SD.
§P < .001 for group PMS1−35 versus group PMV1−35; ∗∗P < .001 for
group PMS21−35 versus group PMV21−35; ∗∗∗P < .001 for group PMS21−35 versus group PM1−35.418 B. Liu et al.
FIGURE 3 Simvastatin prevents the development of small pulmonary artery hypertrophy in pneu-
monectomized, MCT-treated rats. (A) Control; (B)P M V 1−35;( C)P M V 21−35;( D)P M 1−35;(E)P M S 1−35;
(F)P M S 21−35. Elastin–van Gieson staining (magniﬁcation, × 200) images show reduced small pul-
monary artery hypertrophy in Groups PMS1−35 and PMS21−35.
Simvastatin Decreased Medial Hypertrophy
Prominent medial wall hypertrophy was evident in muscular pulmonary
arteries from diseased rats (Figure 3A to F). The percent medial wall thick-
ness (%WT) of rats in groups PM1−21 and PM1−35 was signiﬁcantly higher
than that of respective control animals (Figure 4A).
In contrast, rats treated with simvastatin (groups PMS1−35 and
PMS21−35) demonstrated decreased medial hypertrophy at different degree
FIGURE 4 Reduced percent medial wall thickness of small pulmonary artery hypertrophy in pneu-
monectomized, MCT-treated rats by simvastatin. Small pulmonary artery (50 to 150 µm) hypertrophy
measured by (2 × medial thickness/external diameter) × 100. (A) Percent medial wall thickness is
shown among the 3 groups of rats as stated in Figure 1A. Bars are means ± SD. ∗P < .001 for Groups
PM1−21 and PM1−35 versus control; #P < .001 for group PM1−35 versus group PM1−21.( B) Percent me-
dial wall thickness is shown among the 5 groups of rats as stated in Figure 1B. Bars are means ± SD. Sim-
vastatin alleviated arterial medial hypertrophy in pneumonectomized, monocrotaline-treated rats (
§P <
.001 for group PMS1−35 versus group PMV1−35; P < .001 for group PMS21−35 versus group PMV21−35).
Group PMS1−35 had signiﬁcantly lower percent medial wall thickness than group PMS21−35 (∗∗∗P < .05).Simvastatin and GATA-6 Expression in PH Rats 419
(Figure 4B), whereas rats treated with vehicle (groups PMV21−35 and
PMV1−35) demonstrated signiﬁcant medial hypertrophy (Figure 4B).
Histopathology
Representative morphologies of small pulmonary arteries in normal rats
and rats in groups PM1−35,P M V 1−35,P M V 21−35,P M S 1−35,a n dP M S 21−35 are
shown to be stained for elastin-van Gieson to reveal the inner elastin lamina
(Figure 5A to F). A quantitative analysis of luminal obstruction on 50 con-
secutive small pulmonary arteries from each rat was performed (Figure 5G).
The distribution of the vascular lesions, and an average vascular occlusion
score (between 0 and 2), are presented (Figure 5A to F). The pneumonec-
tomized, MCT-treated rats resulted in severe changes of neointimal prolif-
eration and vascular occlusion (Figure 5B versus A). The vascular occlusion
score (VOS) in groups PMV1−35 and PMV21−35 was similar to an average
VOS for our laboratory’s historical data on group PM1−35 rats (Figure 5C
and D versus B). This suggests that the treatment of vehicle does not alter
the histopathology of this disease model. Compared with groups PMV1−35
and PMV21−35, groups PMS1−35 and PMS21−35 had a lower VOS, respectively
(Figure 5G).
GATA-6 Gene Expression in the Lung Tissue
Changes in lung GATA-6 mRNA expression were assessed semiquanti-
tatively by RT-PCR (Figure 6A). The expression of GATA-6 mRNA, normal-
ized to β-actin expression, was signiﬁcantly lower in diseased rats (groups
PM1−21 and PM1−35) than in normal rats (Figure 6B). Simvastatin treatment
increased the expression of GATA-6 mRNA in MCT-treated, pneumonec-
tomized rats (Figure 6C).
The lung expression of GATA-6 protein was assessed qualitatively by
Western blotting (Figure 7A). A GATA-6 antiserum-immunoreactive band
is detected at 56 kDa (Figure 7A). Compared with normal rats, diseased
rats in groups PM1−21 and PM1−35 showed decreased expression of GATA-6
protein (Figure 7B). Simvastatin treatment signiﬁcantly increased GATA-6
protein expression (Figure 7C).
DISCUSSION
Pulmonary arterial hypertension is characterized histopathologically by
changes of abnormal proliferation of vascular endothelial and smooth mus-
cle cells, occlusion of microvascular pulmonary arteries, and plexiform le-
sion formation in severe cases. Although the pathogenesis of most forms
of pulmonary arterial hypertension is unknown, there have been many re-
cent developments in pathogenesis involving inappropriate proliferation420 B. Liu et al.
FIGURE 5 Simvastatin suppresses the development of pulmonary arterial neointimal formation. The
vascular occlusion score (VOS) was the average of 50 consecutive intra-acinar pulmonary arteries.
(A) Normal rat intra-acinar artery without evidence of neointimal proliferation (grade 0). (B,C, and
D) Grade 2 neointimal lesions (>50% luminal occlusion) in groups PM1−35,P M V 1−35,a n dP M V 21−35.
(E) Predominance of grade 2 lesson in group PMS21−35.( F) Grade 1 neointimal lesion (<50% lumenal
occlusion) in group PMS1−35. All samples were stained with EVG. The images are × 400 magniﬁcation.
(G) Average grades of VOS among the 6 groups of rats as stated in Figure 1A and B. ∗P < .001 for
group PM1−35 versus control; ∗P < .001 for group PMS1−35 versus group PMV1−35; ∗P < .001 for group
PMS21−35 versus group PMV21−35; ∗P < .001 for group PMS1−35 versus group PMS21−35, respectively.
and constriction of vascular smooth muscle cells, and deﬁciencies of en-
dogenous vasodilators such as prostacyclin and endothelial-derived nitric
oxide [39], especially pertaining to the molecular genetics and cell biol-
ogy of idiopathic pulmonary arterial hypertension. The increase in pul-
monary arterial pressure leads to right ventricular congestive failure and
ultimately to death. Current treatment strategies for PAH include diuretics,
anticoagulation, digoxin, and supplemental oxygen for congestive heart fail-
ure, and pulmonary vasodilating agents such as calcium channel antagonistsSimvastatin and GATA-6 Expression in PH Rats 421
FIGURE 6 Reduction in GATA-6 mRNA expression during the development of pulmonary hyperten-
sion in pneumonectomized, MCT-treated rats that was reversed by simvastatin. (A) RT-PCR analysis of
GATA-6 and β-actin gene expression in representative rat lungs from groups stated in Figure 1A and
B.( B) Relative abundance of GATA-6/β-actin mRNA expression among the 3 groups of rats stated
in Figure 1A. Mean and standard deviation of GATA-6 mRNA expression normalized to β-actin is
shown (n = 3/group). ∗P < .001 for groups PM1−21 and PM1−35 versus control; #P < .01 for group
PM1−35 versus group PM1−21.( C) Relative abundance of GATA-6/β-actin mRNA expression among the
5 groups of rats stated in Figure 1B. Mean and standard deviation of GATA-6 mRNA expression nor-
malized to β-actin is shown (n = 3/group). Simvastatin restored GATA6 mRNA expression level in dis-
eased rats (∗∗P < .001 for group PMS1−35 versus group PMV1−35;
§P < .001 for group PMS21−35 versus
group PMV21−35). Group PMS1−35 had signiﬁcantly higher GATA-6 mRNA expression level than Group
PMS21−35 (∗∗∗P < .01).422 B. Liu et al.
FIGURE 7 Decrease in GATA-6 protein expression during the development of pulmonary hypertension
in pneumonectomized, MCT-treated rats that was restored by simvastatin. (A) Western blotting analysis
of GATA-6 protein expression in representative rat lung protein extracts from each group as stated in
Figure 1A and B.( B) Relative abundance of GATA-6/β-actin protein expression among the three groups
of rats stated in Figure 1A. Mean and standard deviation of GATA-6 protein expression normalized to
β-actin is shown (n = 3/group). ∗P < .001 for group PM1−35 versus control; ∗∗P < .01 for group PM1−21
versus control; #P < .01 for group PM1−35 versus group PM1−21.( C) Relative abundance of GATA-6/
β-actin protein expression among the 5 groups of rats stated in Figure 1B. Mean and standard devia-
tion of GATA-6 protein expression normalized to β-actin is shown (n = 3/group). Simvastatin restored
GATA-6 protein expression level in diseased rats (∗∗∗P < .001 for group PMV1−35 versus group PMS1−35;
§P < .001 for group PMV21−35 versus group PMS21−35). Group PMS1−35 had signiﬁcantly higher GATA-6
protein expression level than group PMS21−35 (∗∗∗∗P < .01).
and prostanoids, especially intravenous (IV) epoprostenol and endothelin-
receptor antagonists. New therapies, especially theose directing at suppress-
ing inappropriate neointimal proliferation in pulmonary arteries, are war-
ranted [40–43].
Statins, the HMG CoA reductase inhibitors, have had a dramatic
impact on clinical outcomes in patients with coronary artery disease.Simvastatin and GATA-6 Expression in PH Rats 423
Several studies have documented beneﬁts unrelated to cholesterol lower-
ing [44, 45], with multiple “pleiotropic” effects on vascular wall function
that would be expected to attenuate vascular remodeling [46]. These effects
stem from their ability to reduce the production of the isoprenoid inter-
mediates farnesyl and geranylgeranyl pyrophosphate, compounds that are
distal to mevalonate in the cholesterol synthetic pathway. These lipophilic
molecules are then covalently bound to Rho and other small G proteins in
a post-translational modiﬁcation that is essential for attachment of these im-
portant signaling proteins to cell membranes and regulators and for their
activation of downstream effectors [47].
In present study, we probed the hypothesis that statins could attenu-
ate vascular remodeling and pulmonary hypertension in a rat model of
neointimal pulmonary hypertension. Simvastatin administration produced
a marked reduction in pulmonary artery pressure developed in animals with
pneumonectomy and MCT administration. Simvastatin also signiﬁcantly
reduced the right ventricular hypertrophy, as indicated by the RV/(LV +
S) weight ratio. Morphological analysis of the pulmonary vasculature of
simvastatin-treated rats revealed considerable decrease in medial thickness
of medium-sized arteries and neointimal formation. We also found that
GATA-6 mRNA and protein expression dramatically decreased in pneu-
monectomized, MCT-treated rats that was restored by simvastatin adminis-
tration.
The exact mechanism of attenuation of neointimal pulmonary hyper-
tension by simvastatin was not understood. Several actions of statins could
account for our observations. Statins have been noted to reduce blood pres-
sure in spontaneously hypertensive but not normotensive rats [38]. Simvas-
tatin treatment potently inhibits vascular remodeling by attenuates chronic
hypoxic pulmonary hypertension and polycythemia in rats [33], and re-
verses pulmonary arterial neointimal formation and PAH after toxic in-
jury by down-regulating the inﬂammatory genes fos, jun, and tumor necro-
sis factor-α and up-regulating the cell cycle inhibitor p27Kip1, endothelial
nitric oxide synthase, and bone morphogenetic protein receptor type 1a
[31]. Inhibition of HMG-CoA reductase by statins decreases isoprenoid in-
termediates such as farnesyl-PP and geranylgeranyl-PP, which leads to an
inhibition of isoprenylation of small GTPases such as Ras, Rho, Rab, and
Rap. Among the Rho GTPases are RhoA, Rac1, and Cdc42 [48]. Statins
have been shown to induce apoptosis of pulmonary vascular smooth muscle
cells in serum-free medium [49]. Both endothelin-1 [50] and endothelin
receptor [51] transcriptions are reduced by statins, which would attenuate
chronic hypoxic pulmonary hypertension. Simvastatin markedly decreased
the platelet-derived growth factor–induced proliferation of vascular smooth
muscle cells by preventing Rho GTPase-induced downregulation of p27kip1,
an important negative regulator of cell proliferation [28]. Simvastatin is also
demonstrated to regulate the differentiation and the phenotype expression424 B. Liu et al.
of VSMCs [34]. In addition, statins have potent antioxidant effects [52].
Given that oxidative stress may be an important mediator of chronic hypoxic
pulmonary hypertension [38] as well as acute hypoxic pulmonary vasocon-
striction [53], the antioxidant effect of simvastatin may also play a role in
attenuation of pulmonary hypertension observed here.
In this study, we found that down-regulation of GATA-6 expression was
concurrent with development and progression of pulmonary hypertension,
right ventricular hypertrophy, arterial medial hypertrophy, and neointimal
formation in the neointimal pulmonary hypertensive model. GATA-6 gene
expression has been detected in the pericardial mesoderm, embryonic heart
tube, and primitive gut during early embryonic development [54]. How-
ever, during development, GATA-6 becomes the only member of the fam-
ily expressed in vascular smooth muscle cells [15, 55] and its expression
is down-regulated in proliferating vascular smooth muscle cells [18]. These
data suggest that down-regulation of GATA-6 expression is closely associated
with pulmonary arterial smooth muscle cells proliferation and that the level
of GATA-6 expression may be an indicator of severity of hypertensive pul-
monary vascular disease.
Some recent reports show that simvastatin up-regulates GATA-3 expres-
sion in dendritic cells and up-regulates the binding activity of GATA-6 to SM-
MHC GATA site, whereas mutating the GATA-6 binding site abolished this
activation [34, 56]. In the present study, we also found that down-regulation
of GATA-6 expression was reversed in pulmonary hypertensive rats treated
with simvastatin. However, the precise mechanism that statins regulate ex-
pression of GATA family members is unknown. Further studies will be per-
formed to investigate the mechanism of GATA-6 expression by regulated
by simastatin and examine GATA-6 expression in the lung tissue of human
patients with pulmonary hypertension.
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